Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 89105-94-2
2. Chembl409436
3. Fibrinogen-binding Inhibitor Peptide
4. Dtxsid10433062
5. Hishisleuglyglyalalysglnalaglyaspval
6. Bdbm50034686
7. Mfcd00167528
8. Ncgc00167215-01
| Molecular Weight | 1189.3 g/mol |
|---|---|
| Molecular Formula | C50H80N18O16 |
| XLogP3 | -9.7 |
| Hydrogen Bond Donor Count | 18 |
| Hydrogen Bond Acceptor Count | 20 |
| Rotatable Bond Count | 39 |
| Exact Mass | 1188.59996854 g/mol |
| Monoisotopic Mass | 1188.59996854 g/mol |
| Topological Polar Surface Area | 547 Ų |
| Heavy Atom Count | 84 |
| Formal Charge | 0 |
| Complexity | 2310 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 9 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33614
Submission : 2019-05-27
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33983
Submission : 2019-07-22
Status : Active
Type : II

Registration Number : 227MF10083
Registrant's Address : 1-6-1 Okubo, Kita-ku, Kumamoto City, Kumamoto Prefecture
Initial Date of Registration : 2015-03-12
Latest Date of Registration :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33614
Submission : 2019-05-27
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33983
Submission : 2019-07-22
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Human fibrinogen drug substance
Registration Number : 227MF10083
Registrant's Address : 1-6-1 Okubo, Kita-ku, Kumamoto City, Kumamoto Prefecture
Initial Date of Registration : 2015-03-12
Latest Date of Registration : 2016-03-23

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Fibryga is a fibrinogen concentrate which acts as as fibrinogen replacement therapy. It is approved for the treatment of acquired fibrinogen deficiency (AFD).
Lead Product(s): Fibrinogen,Inapplicable
Therapeutic Area: Hematology Brand Name: Fibryga
Study Phase: Approved FDFProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 01, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fibrinogen,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Fibryga® for Fibrinogen Supplementation in Acquired Deficiency
Details : Fibryga is a fibrinogen concentrate which acts as as fibrinogen replacement therapy. It is approved for the treatment of acquired fibrinogen deficiency (AFD).
Product Name : Fibryga
Product Type : Protein
Upfront Cash : Inapplicable
August 01, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The supplement approvals resulted in new product labeling for Octaplas™, Pooled Plasma (Human), Solvent/Detergent (S/D) Treated Solution for Intravenous Infusion, and fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution.
Lead Product(s): Fibrinogen,Inapplicable
Therapeutic Area: Hematology Brand Name: Fibryga
Study Phase: Phase IIIProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 29, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fibrinogen,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approvals Strengthen Octapharma USA Pediatric Critical Care Product Portfolio
Details : The supplement approvals resulted in new product labeling for Octaplas™, Pooled Plasma (Human), Solvent/Detergent (S/D) Treated Solution for Intravenous Infusion, and fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution.
Product Name : Fibryga
Product Type : Protein
Upfront Cash : Inapplicable
March 29, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Octapharma to present multiple clinical trial posters on the efficacy and safety of fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for Intravenous Use to treat congenital and acquired bleeding disorders.
Lead Product(s): Fibrinogen,Inapplicable
Therapeutic Area: Hematology Brand Name: Fibryga
Study Phase: Approved FDFProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 03, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fibrinogen,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Octapharma USA Presents Research on Congenital & Acquired Bleeding Disorders at ASH Annual Meeting
Details : Octapharma to present multiple clinical trial posters on the efficacy and safety of fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for Intravenous Use to treat congenital and acquired bleeding disorders.
Product Name : Fibryga
Product Type : Protein
Upfront Cash : Inapplicable
December 03, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Afibrinogenemia.
Lead Product(s): Fibrinogen,Inapplicable
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 19, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fibrinogen,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis
Details : Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Afibrinogenemia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 19, 2020

Details:
Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhage.
Lead Product(s): Fibrinogen,Prothrombin Complex Concentrate
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Protein
Sponsor: Sunnybrook Health Sciences Centre | Octapharma | Canadian Institutes of Health Research | Canadian Institute for Military and Veteran Health Research Defense Research & Development Canada
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 01, 2020

Lead Product(s) : Fibrinogen,Prothrombin Complex Concentrate
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Sunnybrook Health Sciences Centre | Octapharma | Canadian Institutes of Health Research | Canadian Institute for Military and Veteran Health Research Defense Research & Development Canada
Deal Size : Inapplicable
Deal Type : Inapplicable
Factor In the Initial Resuscitation of Severe Trauma 2 Patients
Details : Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhage.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 01, 2020

Details:
Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Huntington Disease.
Lead Product(s): Fibrinogen,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Protein
Sponsor: Octapharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 06, 2020

Lead Product(s) : Fibrinogen,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Octapharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients
Details : Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Huntington Disease.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 06, 2020

Details:
Riastap (Fibrinogen) is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Postpartum Hemorrhage.
Lead Product(s): Fibrinogen,Inapplicable
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Riastap
Study Phase: Phase I/ Phase IIProduct Type: Protein
Sponsor: CSL Behring
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 19, 2015

Lead Product(s) : Fibrinogen,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : CSL Behring
Deal Size : Inapplicable
Deal Type : Inapplicable
A Program to Evaluate Riastap® and FIBTEM® for the Early Control and Treatment of Postpartum...
Details : Riastap (Fibrinogen) is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Postpartum Hemorrhage.
Product Name : Riastap
Product Type : Protein
Upfront Cash : Inapplicable
August 19, 2015

Details:
Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Wounds and Injuries.
Lead Product(s): Fibrinogen,Inapplicable
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Protein
Sponsor: CSL Behring
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 22, 2015

Lead Product(s) : Fibrinogen,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : CSL Behring
Deal Size : Inapplicable
Deal Type : Inapplicable
Pilot Randomized Trial of Fibrinogen in Trauma Haemorrhage
Details : Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Wounds and Injuries.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 22, 2015

Details:
Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Wounds and Injuries.
Lead Product(s): Fibrinogen,Inapplicable
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 30, 2014

Lead Product(s) : Fibrinogen,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Fibrinogen in the Initial Resuscitation of Severe Trauma (FiiRST)
Details : Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Wounds and Injuries.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 30, 2014

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Thrombin is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhage.
Lead Product(s): Thrombin,Fibrinogen
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Undisclosed
Sponsor: Johnson & Johnson
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 24, 2014

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Thrombin,Fibrinogen
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Thrombin is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhage.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 24, 2014

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Tisseel
Dosage Form : POW
Dosage Strength : 72-110mg/ml
Packaging : 2X1mg/ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Tisseel
Dosage Form : POW
Dosage Strength : 72-110mg/ml
Packaging : 4X1mg/ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorised
Registration Country : Malta
Brand Name : Riastap
Dosage Form : Powder For Solution For Injection And Infusion
Dosage Strength : 1G
Packaging :
Approval Date : 2017-01-19
Application Number :
Regulatory Info : Authorised
Registration Country : Malta

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorised
Registration Country : Malta
Brand Name : Fibryga
Dosage Form : Powder And Solvent For Injectable Solution And Infusion
Dosage Strength : 20MG/ML
Packaging :
Approval Date : 2022-08-10
Application Number :
Regulatory Info : Authorised
Registration Country : Malta

Regulatory Info :
Registration Country : Norway
Fibrinogen, human, Thrombin, human
Brand Name : TachoSil
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Packaging : Boks 5 7.5cm2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Fibrinogen, human, Thrombin, human
Brand Name : TachoSil
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Packaging : Boks 1 45.6cm2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Fibrinogen, human, Thrombin, human
Brand Name : TachoSil
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Packaging : Boks 1 7.5cm2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Fibrinogen, human, Thrombin, human
Brand Name : TachoSil
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Packaging : Boks 1 23cm2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Fibrinogen, human, Thrombin, human
Brand Name : TachoSil
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Packaging : Boks 2 23cm2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]https://www.pharmacompass.com/radio-compass-blog/fda-okays-50-new-drugs-in-2024-bms-cobenfy-lilly-s-kisunla-lead-pack-of-breakthrough-therapies
Global Sales Information
Corza Medical GmbH
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Price Per Pack (Euro) : 248.11
Published in :
Country : Norway
RX/OTC/DISCN :

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Corza Medical GmbH
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Price Per Pack (Euro) : 214.24
Published in :
Country : Norway
RX/OTC/DISCN :

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Corza Medical GmbH
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Price Per Pack (Euro) : 49.62
Published in :
Country : Norway
RX/OTC/DISCN :

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Corza Medical GmbH
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Price Per Pack (Euro) : 170.44
Published in :
Country : Norway
RX/OTC/DISCN :

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Corza Medical GmbH
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Price Per Pack (Euro) : 249.29
Published in :
Country : Norway
RX/OTC/DISCN :

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Human Thrombin, Human Fibrogen
Main Therapeutic Indication :
Currency : USD
2016 Revenue in Millions : Not Reported
2015 Revenue in Millions : 40
Growth (%) : -100

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2022-01-25
Date Granted : 2009-04-21
FIBRINOGEN (HUMAN), THROMBIN (HUMAN), COLLAGEN
Brand Name : TACHOSIL
Patent Number : 2434964
Filing Date : 2002-01-25
Strength per Unit : (9.5 cm x 4.8 cm) per cm?: 5.5 mg / 2.0 IU & 2.1mg
Dosage Form : PATCH
Human Or VET : Human
Route of Administration : TOPICAL
Patent Expiration Date : 2022-01-25
Date Granted : 2009-04-21

Patent Expiration Date : 2022-01-25
Date Granted : 2009-04-21
FIBRINOGEN (HUMAN), THROMBIN (HUMAN), COLLAGEN
Brand Name : TACHOSIL
Patent Number : 2434964
Filing Date : 2002-01-25
Strength per Unit : (4.8 cm x 4.8 cm) per cm?: 5.5 mg / 2.0 IU & 2.1 m
Dosage Form : PATCH
Human Or VET : Human
Route of Administration : TOPICAL
Patent Expiration Date : 2022-01-25
Date Granted : 2009-04-21

Patent Expiration Date : 2022-01-25
Date Granted : 2009-04-21
FIBRINOGEN (HUMAN), THROMBIN (HUMAN), COLLAGEN
Brand Name : TACHOSIL
Patent Number : 2434964
Filing Date : 2002-01-25
Strength per Unit : (3.0 cm x 2.5 cm) per cm?: 5.5 mg, 2.0 IU & 2.1 mg
Dosage Form : PATCH
Human Or VET : Human
Route of Administration : TOPICAL
Patent Expiration Date : 2022-01-25
Date Granted : 2009-04-21

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
68
PharmaCompass offers a list of Fibrinogen API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Fibrinogen manufacturer or Fibrinogen supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fibrinogen manufacturer or Fibrinogen supplier.
PharmaCompass also assists you with knowing the Fibrinogen API Price utilized in the formulation of products. Fibrinogen API Price is not always fixed or binding as the Fibrinogen Price is obtained through a variety of data sources. The Fibrinogen Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Fibrinogen manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fibrinogen, including repackagers and relabelers. The FDA regulates Fibrinogen manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fibrinogen API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Fibrinogen supplier is an individual or a company that provides Fibrinogen active pharmaceutical ingredient (API) or Fibrinogen finished formulations upon request. The Fibrinogen suppliers may include Fibrinogen API manufacturers, exporters, distributors and traders.
click here to find a list of Fibrinogen suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Fibrinogen DMF (Drug Master File) is a document detailing the whole manufacturing process of Fibrinogen active pharmaceutical ingredient (API) in detail. Different forms of Fibrinogen DMFs exist exist since differing nations have different regulations, such as Fibrinogen USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Fibrinogen DMF submitted to regulatory agencies in the US is known as a USDMF. Fibrinogen USDMF includes data on Fibrinogen's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fibrinogen USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Fibrinogen suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Fibrinogen Drug Master File in Japan (Fibrinogen JDMF) empowers Fibrinogen API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Fibrinogen JDMF during the approval evaluation for pharmaceutical products. At the time of Fibrinogen JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Fibrinogen suppliers with JDMF on PharmaCompass.
Fibrinogen Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fibrinogen GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fibrinogen GMP manufacturer or Fibrinogen GMP API supplier for your needs.
A Fibrinogen CoA (Certificate of Analysis) is a formal document that attests to Fibrinogen's compliance with Fibrinogen specifications and serves as a tool for batch-level quality control.
Fibrinogen CoA mostly includes findings from lab analyses of a specific batch. For each Fibrinogen CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fibrinogen may be tested according to a variety of international standards, such as European Pharmacopoeia (Fibrinogen EP), Fibrinogen JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fibrinogen USP).